» Articles » PMID: 33805039

Nutraceutical, Dietary, and Lifestyle Options for Prevention and Treatment of Ventricular Hypertrophy and Heart Failure

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Apr 3
PMID 33805039
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Although well documented drug therapies are available for the management of ventricular hypertrophy (VH) and heart failure (HF), most patients nonetheless experience a downhill course, and further therapeutic measures are needed. Nutraceutical, dietary, and lifestyle measures may have particular merit in this regard, as they are currently available, relatively safe and inexpensive, and can lend themselves to primary prevention as well. A consideration of the pathogenic mechanisms underlying the VH/HF syndrome suggests that measures which control oxidative and endoplasmic reticulum (ER) stress, that support effective nitric oxide and hydrogen sulfide bioactivity, that prevent a reduction in cardiomyocyte pH, and that boost the production of protective hormones, such as fibroblast growth factor 21 (FGF21), while suppressing fibroblast growth factor 23 (FGF23) and marinobufagenin, may have utility for preventing and controlling this syndrome. Agents considered in this essay include phycocyanobilin, N-acetylcysteine, lipoic acid, ferulic acid, zinc, selenium, ubiquinol, astaxanthin, melatonin, tauroursodeoxycholic acid, berberine, citrulline, high-dose folate, cocoa flavanols, hawthorn extract, dietary nitrate, high-dose biotin, soy isoflavones, taurine, carnitine, magnesium orotate, EPA-rich fish oil, glycine, and copper. The potential advantages of whole-food plant-based diets, moderation in salt intake, avoidance of phosphate additives, and regular exercise training and sauna sessions are also discussed. There should be considerable scope for the development of functional foods and supplements which make it more convenient and affordable for patients to consume complementary combinations of the agents discussed here. Key word searching of PubMed was employed to locate the research papers whose findings are cited in this essay.

Citing Articles

Impact of Exercise on Physiological, Biochemical, and Analytical Parameters in Patients with Heart Failure with Reduced Ejection Fraction.

Epelde F Medicina (Kaunas). 2025; 60(12.

PMID: 39768897 PMC: 11728036. DOI: 10.3390/medicina60122017.


Loss of Trim31 Worsens Cardiac Remodeling in a Mouse Model of Heart Failure by Enhancing the Activation of the NLRP3 Inflammasome.

Duan F, Li H, Lu B, Wang X, Xu X Inflammation. 2024; .

PMID: 39673012 DOI: 10.1007/s10753-024-02217-w.


Nutritional and Nutraceutical Support to the Failing Myocardium: A Possible Way of Potentiating the Current Treatment of Heart Failure.

Macri R, Mollace R, Serra M, Scarano F, Ritorto G, Ussia S Int J Mol Sci. 2024; 25(22).

PMID: 39596298 PMC: 11594499. DOI: 10.3390/ijms252212232.


Astaxanthin Supplementation Effects in Right Ventricle of Rats Exposed to Chronic Intermittent Hypobaric Hypoxia.

Pena E, El Alam S, Gonzalez C, Cortes I, Aguilera D, Flores K Antioxidants (Basel). 2024; 13(10).

PMID: 39456521 PMC: 11504862. DOI: 10.3390/antiox13101269.


A personalized mRNA signature for predicting hypertrophic cardiomyopathy applying machine learning methods.

Gu J, Zhao Y, Ben Y, Zhang S, Hua L, He S Sci Rep. 2024; 14(1):17023.

PMID: 39043774 PMC: 11266364. DOI: 10.1038/s41598-024-67201-8.


References
1.
Bakker J, Bondonno N, Gaspari T, Kemp-Harper B, McCashney A, Hodgson J . Low dose dietary nitrate improves endothelial dysfunction and plaque stability in the ApoE mouse fed a high fat diet. Free Radic Biol Med. 2016; 99:189-198. DOI: 10.1016/j.freeradbiomed.2016.08.009. View

2.
Ellam T, Chico T . Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis. 2011; 220(2):310-8. DOI: 10.1016/j.atherosclerosis.2011.09.002. View

3.
Li W, Fang Q, Zhong P, Chen L, Wang L, Zhang Y . EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice. Sci Rep. 2016; 6:24580. PMC: 5263857. DOI: 10.1038/srep24580. View

4.
Wang H, Lu X, Lu D, Qi R, Wang Y, Fu Y . Glycine inhibits the LPS-induced increase in cytosolic Ca2+ concentration and TNFalpha production in cardiomyocytes by activating a glycine receptor. Acta Pharmacol Sin. 2009; 30(8):1107-14. PMC: 4006684. DOI: 10.1038/aps.2009.106. View

5.
Umar S, van der Laarse A . Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2009; 333(1-2):191-201. DOI: 10.1007/s11010-009-0219-x. View